Chronic Kidney Disease (Chronic Renal Failure) Pipeline Report - H1 2016 Review of 30 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Chronic Kidney Disease (Chronic Renal Failure) Overview
  3. Therapeutics Development
  4. Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview
  5. Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis
  6. Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies
  7. Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes
  8. Chronic Kidney Disease (Chronic Renal Failure) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies
  13. Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes
  14. Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
  • Acceleron Pharma, Inc.
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-inRen
  • BioAegis Therapeutics, Inc.
  • Boryung Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Lupin Limited
  • Nippon Zoki Pharmaceutical Co., Ltd.
  • OPKO Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • Prismic Pharmaceuticals, Inc.
  • Prolong Pharmaceuticals, LLC
  • ProMetic Life Sciences Inc.
  • Reata Pharmaceuticals, Inc.
  • Red Glead Discovery AB
  • RegenMedTX, LLC
  • Resverlogix Corp.
  • Sphaera Pharma Pvt. Ltd.
  • Stelic Institute & Co., Inc.
  • Thrasos Therapeutics Inc.
  • Toray Industries, Inc.
  • VBS Pharmaceuticals
  • Vicore Pharma AB

For more information visit http://www.researchandmarkets.com/research/92lwt6/chronic_kidney

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Liver and Kidney Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Liver and Kidney Disorders Drugs